KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aquestive Therapeutics (AQST) Operating Expenses (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Operating Expenses data on record, last reported at $41.9 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 64.48% year-over-year to $41.9 million; the TTM value through Dec 2025 reached $115.6 million, up 30.87%, while the annual FY2025 figure was $115.6 million, 30.87% up from the prior year.
  • Operating Expenses reached $41.9 million in Q4 2025 per AQST's latest filing, up from $24.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $41.9 million in Q4 2025 and bottomed at $15.4 million in Q3 2023.
  • Average Operating Expenses over 5 years is $22.2 million, with a median of $21.4 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: crashed 32.95% in 2023, then soared 64.48% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $22.7 million in 2021, then fell by 5.94% to $21.4 million in 2022, then decreased by 20.0% to $17.1 million in 2023, then surged by 48.66% to $25.4 million in 2024, then skyrocketed by 64.48% to $41.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $41.9 million in Q4 2025, $24.3 million in Q3 2025, and $21.4 million in Q2 2025.